Table 1.
Marketed liposomal productsa.
| Product (manufacturer) | Drug | Indications | Year approvedb |
|---|---|---|---|
| AmBisome (Gilead) | Amphotericin B | Fungal infections and Leishmaniasis | 1990 (Europe), 1997 (USA) |
| Doxil (Johnson&Johnson) | Doxorubicin | Kaposi's sarcoma | 1995 |
| Ovarian cancer | 1999 | ||
| Breast Cancer | 2003 | ||
| Multiple myeloma + Velcade | 2007 (Europe, Canada) | ||
| DaunoXome (Galen) | Daunorubicin | Kaposi's sarcoma | 1996 (Europe), 1996 (USA) |
| Myocet (Cephalon) | Doxorubicin | Breast cancer+cyclophosphamide | 2000 (Europe) |
| Epaxal (Crucell, Switzerland) | Virosome | Hepatitis A virus | 1994 (Europe) |
| Inflexal (Crucell, Switzerland) | Virosome | Influenza virus | 1997 (Europe) |
| Nasalflu | Virosome | Influenza virus (Intranasal application) | 2000 (Europe, withdrawn in 2001) |
| Amphotec (Intermune) | Amphotericin B | Invasive aspergillosis | 1996 |
| Abelcet (Enzon) | Amphotericin B | Aspergillosis | 1995 |
| Visudyne (QLT) | Verteporphin | Wet macular degeneration | 2000 (USA), 2003 (Japan) |
| DepoDur (Pacira) | Morphine sulfate | Pain following surgery | 2004 |
| DepoCyt (Pacira) | Cytosine Arabinoside | Lymphomatous or Neoplastic meningitis | 1999 |
| Exparel (Pacira) | Bupivacaine | Post-surgical pain | 2011 |
| Lipo-Dox (TLC, Taiwan) | Doxorubicin | Kaposi's sarcoma, breast and ovarian cancer | 2002 (Taiwan) |
| Lipusu (Luye Pharma, China) | Paclitaxel | Ovarian cancer | 2003 (China) |
| Breast cancer | |||
| Non-small cell lung cancer (NSCLC) | |||
| Mepact (Takeda) | Muramyl tripeptide-PE | Nonmetastatic, resectable osteosarcoma | 2009 (Europe) |
| Marqibo (Talon) | Vincristine | Acute lymphoblastic leukemia | 2012 |
| Onivyde (Merrimack) | Irinotecan | Pancreatic cancer | 2015 |
| Vyxeos (Jazz/Celator) | Ara-C/DNR (5:1) | Acute myeloid leukemia (AML) | 2017 |
| Mosquirix (GlaxoSmithKline) | HBsAg-VLP/MPLA/CSP | Malaria | 2015 |
| Shringrix (GlaxoSmithKline) | MPLA/QS21/gE | Shingles | 2017 |
| Onpattro (Alnylam) | siRNA | Polyneuropathy (Hereditary transthyretin amyloidosis) | 2018 |
a
World-widely, there are also several approved generic liposome products, and they are not listed here owing to lack of novelty.
b
The product was licensed in USA unless an annotation indicates where it was.